OBJECTIVE

Analysis of clinical and hemodynamic results of aortic (AVR), mitral (MVR) and tricuspid valve (TVR) replacement with epoxy-treated xenopericardial biological prosthesis «UniLine».

MATERIAL AND METHODS

A single-center cohort retrospective study included 74 patients who underwent AVR (n=41), MVR (n=26) and TVR (n=7) with UniLine bioprosthesis at the Interregional Clinical Diagnostic Center for the period from June 2017 to September 2019. Mean age of patients was 67.9±9.2 years (AVR group), 64.4±11.8 years (MVR group) and 42.4±14.7 years (TVR group). Mean follow-up was 2.7±1.2 years and 112.1 patient-years (AVR group), 2.8±0.9 years and 72.5 patient-years (MVR group), 3.2±0.8 years and 22.1 patient-years (TVR group), respectively.

RESULTS

Thirty-day mortality was 2.7% (n=2). There were no in-hospital valve-associated lethal and non-mortal complications (bleeding, embolism, dysfunction, stroke, prosthetic endocarditis). Actuarial 3-year survival rate was 100% in all groups. Actuarial 3-year cumulative freedom from prosthesis-associated, as well as major cardiac and cerebrovascular events was 100% in each group. Hemorrhagic and thromboembolic events were not observed. Maximum pressure gradient on the mitral valve prosthesis after 3 years did not significantly differ from baseline value (11.4±3.2 mm Hg). In case of AVR, maximum pressure gradient was 20.7±7.3, 18.9±4.5 and 16.1±3.2 mm Hg for prostheses 21, 23 and 25 mm after 2 years, respectively. There were no significant differences with baseline values (p<0.05).

CONCLUSION

We demonstrated no valve-associated complications after UniLine bioprosthesis implantation in atrioventricular and aortic positions. Moreover, 3-year survival was 100%. Implantation of UniLine bioprosthesis was not accompanied by thromboembolic and hemorrhagic complications. The design of UniLine bioprosthesis is ergonomic and easy for implantation, while hemodynamic characteristics are similar to the declared technical properties.